Age-dependent changes in the expression of regulatory cell surface ligands in activated human T-cells by unknown
Canaday et al. BMC Immunology 2013, 14:45
http://www.biomedcentral.com/1471-2172/14/45RESEARCH ARTICLE Open AccessAge-dependent changes in the expression of
regulatory cell surface ligands in activated human
T-cells
David H Canaday1,2*, Karen E Parker3, Htin Aung1, Hui Emily Chen2, Dariana Nunez-Medina2
and Christopher J Burant1,4Abstract
Background: The immune system consists of multiple preformed and more specific adaptive immune responses,
which are all subject to both positive and negative regulation. Programmed cell death protein 1 (PD-1) is a cell
surface ligand implicated in the induction of anergy, Inducible T-cell Costimulator (ICOS) plays a stimulatory role in
the development of both CD4+ and CD8+ T-cells, Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) plays a role in
inhibitory regulation of T-cell activity, and T cell immunoglobulin and mucin protein 3 (Tim-3) has been described
as a negative regulatory molecule in CD4+ helper type 1 cells and CD8+ cytotoxic type 1 cells. Each of these
ligands is induced with T-cell activation allowing greater opportunity to have a regulatory role.
Results: Flow cytometry was used to quantitate the expression of PD-1, ICOS, CTLA-4 and Tim-3 in human T-cells
from geriatric and younger subjects both at baseline and after in vitro induction by mitogen. The magnitude of
expression of the molecules increased significantly on activated blasts after mitogen stimulation compared to their
baseline levels in resting cells. The increase in CTLA-4 expressing CD8+ T-cells was significantly higher after in vitro
induction in older persons, while the increase in cells expressing Tim-3 and PD-1 was significantly reduced. In CD4+
T-cells, a greater increase in CTLA-4 expressing cells in older persons was the only difference between the age
groups.
Conclusions: We found several significant changes in the older individuals in regulatory elements of the adaptive
immune system that occur particularly after immune activation. These differences could have ramifications to
autoimmunity as well as immunology against infection and tumors.
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Immuno-dysregulation in older adults leads to increased
incidence of autoimmune diseases and decreased re-
sponses to vaccines such as influenza leading to higher
vaccine failure rates [1,2]. If infected latently with M. tu-
berculosis, they are more likely to lose control of the in-
fection and develop reactivation disease [3]. The positive* Correspondence: david.canaday@case.edu
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PD-1 is a cell surface ligand expressed to some degree
on resting and exhausted T-cells that increases following
T-cell receptor activation [4]. PD-1 binds to its ligands
(PDL1 and 2) to induce both T-cell apoptosis and anergy
through inhibition of IL-2 production [5,6]. ICOS and
CTLA-4 are both members of the CD28/B7 family of
receptors [7]. ICOS plays a stimulatory role in the devel-
opment of both CD4+ and CD8+ cells, and its defi-
ciency leads to a decrease in numbers of memory T-
cells. CTLA-4 plays a role in the inhibitory regulationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Canaday et al. BMC Immunology 2013, 14:45 Page 2 of 5
http://www.biomedcentral.com/1471-2172/14/45of T-cell activity at least partially through its role in the
suppressive functions of Tregs, and is thought to have a
central role in the maintenance of peripheral tolerance [8].
The categorization of Tim-3 as either an inhibitory or
stimulatory co-receptor is less straightforward. Tim-3
was first identified as a T-cell cell surface receptor in-
volved in the regulation of Th1 responses, but has subse-
quently been shown to be expressed and active in
antigen-presenting cells as well [9]. Tim-3 has been
described as a negative regulatory molecule in CD4+
helper type 1 cells and CD8+ cytotoxic type 1 cells,
possibly by inducing cell death in the cells expressing
it or by promoting development of exhaustion [10].
Dysregulation of Tim-3 function has been implicated in
the autoimmune disease multiple sclerosis [11].
It has been reported that the levels of inhibitory co-
receptors in mouse T-cells are increased in aging ani-
mals [12,13], which could explain a general reduction
in immunity and increase in susceptibility to auto-
immune diseases in aging. To elucidate changes in the
adaptive immune system that occur with aging related
to regulatory molecules, we report here the levels of
PD-1, CTLA-4, ICOS and Tim-3 in human peripheral
T-cells in young versus older adults after mitogenic











































Figure 1 Percent of cells expressing CTLA-4, ICOS, Tim-3 or PD-1 in y
activation (B). CD8+ T-cells day 0 (C) and day 3 of activation (D). Day 3 cel
Percentage positive determined by Overton method compared to isotype
in ICOS, Tim-3, PD-1 and n = 19 for CTLA-4. Significant differences between
are noted.Results and discussion
We examined the proportion of CD4+ and CD8+ T-cells
expressing the regulatory markers compared to isotype
control and the mean fluorescence intensity (MFI) of the
expression at day 0 and then after 3 days of activation.
Figure 1A and C demonstrate that at day 0 baseline
there were similar proportions of cells that expressed
each one of these markers between the young and old
except the percentage of ICOS expressing CD4+ T-cells
were higher in young than old (74+ vs. 68%, p = 0.015).
In both age groups and cell types after activation, the
proportion of cells expressing each marker on activated
blasts increased somewhat (Figure 1B and D) compared
to baseline resting cells, but the MFI increase on blasts
was more substantial (Figure 2B and D). In mitogen
stimulated cells after 3 days, CD8+ T-cells (Figure 1D)
had several significant differences between the young
and old groups that included less Tim-3 expressing cells
in the older subjects (60% vs. 39%, p < 0.001) and as well
as a decrease in PD-1 expressing cells (55% vs. 45%, p =
0.04). On the other hand, CTLA-4 expressing cells (88%
vs. 79%, p < 0.002) were increased in the older subjects
compared to the younger ones. The MFI on the acti-
vated CD4+ and CD8+ T-cells was increased substan-















































oung and older subjects. CD4+ T-cells day 0 (A) and day 3 of
ls were gated on CD25+ blasts and day 0 on resting lymphocytes.
control. Mean indicated with the black bar. Each age group has n = 24




















































Figure 2 MFI of PD-1, ICOS and CTLA-4 in young and older subjects. CD4+ T-cells day 0 (A) and day 3 of activation (B). CD8+ T-cells day 0
(C) and day 3 of activation (D). Day 3 cells were gated on CD25+ blasts and day 0 on resting lymphocytes. MFI shown has isotype control MFI
subtracted. Mean indicated with the black bar. Each age group has n = 24 in ICOS, Tim-3, PD-1 and n = 19 for CTLA-4. Significant differences
between young and older groups at the p≤ 0.05 level (two-tailed t-test) are noted.
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with SEB however was only statistically different in the
expression of Tim-3 on CD8+ T-cells with higher
expression on the younger subjects (MFI 1860 vs. 889,
p < 0.003). For these studies we gated on CD25+ blasts
to compare the proportions of cells expressing the regu-
lator molecules. This method was chosen to focus on
the expression of the cells that become activated that
can potentially effect a specific change in the immune
response.
Our observations demonstrate that the most signifi-
cant differences between T-cells in older and younger
adults are in CD8+ cells. The differences demonstrated
here in expression of Tim-3 and ICOS on T-cells be-
tween old and young after activation are novel. Similar
to our study Leng et al. found significantly increased
CTLA-4 after activation however our data found a simi-
lar increase in CTLA-4 regardless of age while their
study had a greater increase in CTLA-4 with age [14].
This difference is possibly explained by a kinetic or tech-
nical difference involving the stimulation and antibody
staining. Dolfi et al. recently reported that resting naïve
CD8+ cells have increased PD-1 expression in older sub-
jects, but they did not see a difference in PD-1 expres-
sion in old vs. young subjects after a 5-hour activation
with influenza [15]. Our study extends this findinglooking at PD-1 expression after a 3-day stimulation.
When focusing on activated CD8+ T cells, old individ-
uals have a small decrease in the percent of cells ex-
pressing PD-1 but not in the MFI of expression between
young and old subjects. This suggests at least on a per
cell basis that the PD-1 expression after activation is
similar between the age groups.
Our results contrast with reported results in murine
splenocytes. Channappanavar et al. found small but sig-
nificant increase in PD-1, ICOS, and CTLA-4 in CD4+
T-cells in older inbred C57 mice [12]. Shimada et al.
found only elevated PD-1 and not CLTA-4 on CD4+ T-
cells in older C57 mice [13]. In contrast to our data they
did not see increases in PD-1 with immune activation.
The differences could be species or tissue vs. blood re-
lated. It does highlight the importance of confirming
animal model data in humans.
We stimulated PBMC with mitogen to create a large
population of activated cells that are readily identifiable
by their CD25 expression to allow us to focus on acti-
vated T-cells. The findings in this study point to poten-
tial differences in patterns of ligand expression that can
be studied in future vaccine or pathogen specific systems
in an antigen specific manner. They may also have rele-
vance in the area of anti-tumor immunity and auto-
immunity. Anti-CTLA-4 monoclonal antibody is Food
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malignant melanoma. Higher induced expression in both
CD4+ and CD8+ T-cells could result in diminished im-
munity in older persons. These differences could result
in clinically significant changes in chronic conditions
that include malignancy, autoimmunity and persistent
infections. These data demonstrate that this area of
aging research requires further investigation.
Conclusions
We found several significant changes in the older indi-
viduals in regulatory elements of CD4+ and CD8+ T
cells. After in vitro stimulation the proportion of
activated CD8+ T cells from older individuals was
significantly increased in CTLA-4 and decreased PD-1
and Tim-3. These differences could have ramifications
to autoimmunity as well as immunology against infec-
tion and tumors.
Methods
Peripheral blood mononuclear cells (PBMC) were iso-
lated and cryopreserved from older adults (n = 27, mean
age 86 years, ranging from 69 through 94 years) and
younger adult controls (n = 37, mean age 34 years, ran-
ging from 22 to 44 years) after obtaining informed con-
sent using the protocols approved by the Institutional
Review Boards of the Veterans Affairs Hospital in
Cleveland and Case Western Reserve University [16]. In-
dividuals on immunomodulatory medications (steroids,
chemotherapy, cytokine inhibitors), with recent infection
or hospitalization were excluded. The older group pri-
marily consisted of patients from the Cleveland VA out-
patient geriatric clinic and the younger subjects were
staff and students at the Cleveland VA and Case
Western Reserve University. After thawing, PBMC were
cultured for 3 days with or without the mitogen
Staphylococcal enterotoxin B (SEB) at 1 μg/ml. Cells
were stained on days 0 and 3 with a viability dye (fixable
LIVE/DEAD violet, Invitrogen), CD8-V500 (BD Biosci-
ences), anti-CD3 APC/CY7, CD4-Alexa 700, CD25-PE/
CY7, anti-PD-1-PerCP/CY5.5, ICOS-FITC, CTLA4-
APC, and Tim-3-PE (Biolegend). Staining for CTLA-4
was performed using Cytofix/cytoperm reagents (BD
Biosciences) according to the manufacture’s instructions
while all other markers were stained only for surface ex-
pression. CTLA-4 is only transiently upregulated on the
cell surface and intracellular staining methods must be
employed to measure the true magnitude of activation-
induced upregulation [17]. Data was acquired on a LSR-
II flow cytometer and analyzed using FlowJo software
(Tree Star).
Comparison was made between the resting non-
activated cells at day 0 and the activated CD25+ T-cells
blasts at day 3. CD3+ cells were gated by size and thenlive dead staining. Cells were then subtyped into CD8+
and CD4+ T-cells. They were analyzed in FlowJo using
the Overton method to determine the percent positive
cells above isotype control. The reported MFI of PD-1,
ICOS, CTLA-4 and Tim-3 has the MFI of the isotype-
control stained cells subtracted. Statistical analysis was
performed with SPSS (IBM) using t-tests. Levene’s test
for equality of variances was applied to each comparison
and the appropriate t-test results chosen.
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